Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism.
- Lutz TA aInstitute of Veterinary Physiology, Vetsuisse Faculty University of Zurich bCenter for Integrative Human Physiology, University of Zurich, Zurich cInstitute for Food Nutrition and Health, Laboratory of Translational Nutritional Biology, ETH Zurich, Schwerzenbach dCenter for Molecular Cardiology, University of Zurich, Schlieren, Switzerland.
- Osto E
- 2016-04-01
Published in:
- Current opinion in lipidology. - 2016
Animals
Eating
Glucagon-Like Peptide 1
Glucagon-Like Peptide 2
Humans
Insulin
Insulin Secretion
Lipid Metabolism
Organ Specificity
English
PURPOSE OF REVIEW
Glucagon-like peptide-1 (GLP-1) is the best known incretin hormone able to potentiate glucose-induced insulin secretion. Moreover, GLP-1 is currently under intensive investigation as a potential crucial mediator of beneficial metabolic effects after bariatric surgery, because of its eating inhibitory, antiobesity, and antidiabetes effects. This review briefly summarizes recent findings on the specific effects of GLP-1 on lipoprotein metabolism. The related hormone GLP-2 is derived from the same precursor gene; its effects on lipoprotein metabolism will also be discussed briefly.
RECENT FINDINGS
Pharmacological activation of the GLP-1 system has beneficial effects on obesity-induced alterations of lipoprotein metabolism. These benefits can be observed with direct GLP-1 receptor agonists like liraglutide or exendin-4, but also with inhibitors of dipeptidyl peptidase IV (DPP-IV), which reduce the breakdown of endogenous GLP-1. The role of GLP-2-related pathways on lipid levels and metabolism are less clear, but some effects (e.g. increased intestinal chylomicron output) are opposite to GLP-1.
SUMMARY
Activation of the GLP-1-dependent pathways may perhaps translate into a lower cardiovascular risk. Understanding how GLP-1 and GLP-2 regulate and interact in the control of lipoprotein metabolism will set the stage for the development of new strategies to treat dyslipidaemia in obesity, diabetes, and other cardiometabolic diseases.
Glucagon-like peptide-1 (GLP-1) is the best known incretin hormone able to potentiate glucose-induced insulin secretion. Moreover, GLP-1 is currently under intensive investigation as a potential crucial mediator of beneficial metabolic effects after bariatric surgery, because of its eating inhibitory, antiobesity, and antidiabetes effects. This review briefly summarizes recent findings on the specific effects of GLP-1 on lipoprotein metabolism. The related hormone GLP-2 is derived from the same precursor gene; its effects on lipoprotein metabolism will also be discussed briefly.
RECENT FINDINGS
Pharmacological activation of the GLP-1 system has beneficial effects on obesity-induced alterations of lipoprotein metabolism. These benefits can be observed with direct GLP-1 receptor agonists like liraglutide or exendin-4, but also with inhibitors of dipeptidyl peptidase IV (DPP-IV), which reduce the breakdown of endogenous GLP-1. The role of GLP-2-related pathways on lipid levels and metabolism are less clear, but some effects (e.g. increased intestinal chylomicron output) are opposite to GLP-1.
SUMMARY
Activation of the GLP-1-dependent pathways may perhaps translate into a lower cardiovascular risk. Understanding how GLP-1 and GLP-2 regulate and interact in the control of lipoprotein metabolism will set the stage for the development of new strategies to treat dyslipidaemia in obesity, diabetes, and other cardiometabolic diseases.
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1097/MOL.0000000000000293
- PMID 27031273
- Persistent URL
- https://sonar.ch/global/documents/181049
Statistics
Document views: 34
File downloads:
- Full-text: 0